GlassScriptPhysician profile
Bassel Abouzeid
NPI 1376160846
$4,730.56
in general payments reported to CMS, 2019-2025
12 companies · $812 in 2025
The $812 reported for 2025 was more than what 89% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $3,919 · 2025: $812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,683 · Food and Beverage: $2,048.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,682.59 |
| Food and Beverage | $2,047.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,999.67 | 2024-2025 | Solyx Sis System, Bulkamid, Upsylon |
| Medical Device Business Services, INC. | $1,485.19 | 2024 | Harmonic |
| Ethicon US, LLC | $713.25 | 2024-2025 | Stratafix, Enseal, Enseal X1 |
| Amgen INC. | $144.13 | 2025 | Evenity, Prolia |
| Minerva Surgical, INC | $118.73 | 2024-2025 | |
| Axonics, INC. | $116.52 | 2024 | Axonics |
| Valencia Technologies Corporation | $48.11 | 2025 | Ecoin Device Kit |
| Organon LLC | $32.17 | 2025 | Nexplanon |
| Vertex Pharmaceuticals Incorporated | $22.71 | 2025 | |
| Exeltis, USA INC. | $18.70 | 2025 | Slynd |
| Hologic Sales and Service, LLC | $16.05 | 2025 | Myosure Tissue Removal Device |
| Biogen, INC. | $15.33 | 2025 | Zurzuvae |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bassel Abouzeid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.